Skip to Main Content

A biotech startup that aims to revive a failed drug candidate with a precision approach to treating Alzheimer’s just brought a big name on board: Nobel laureate Dr. Stanley Prusiner, a pioneer in researching prion diseases.

Prusiner, a biologist based at the University of California, San Francisco, will join Alzheon, Inc. as chair of the scientific advisory board, said Alzheon founder and CEO Dr. Martin Tolar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • My mother has Alzheimer disease, since 2008. She has 72 years old, she does not speak any more. We have visit all fisicians in México but they do not give su any hope. What can l do for my mother? What kind of study she can take?

Comments are closed.